Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty ...

The Washington, DC Department of Health said Tuesday it is investigating a confirmed measles case. The infected person took ...

Colon cancer is the second leading cause of cancer deaths in the U.S., and a new study shows it may also raise the risk of ...

In this week’s edition of InnovationRx, we look at the trend in fatal drug overdoses, 23andMe’s bankruptcy, the new CDC ...

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report), ...

The United States market has experienced a 2.9% increase in the last week and is up 11% over the past year, with earnings projected to grow by 14% annually in the coming years. In this dynamic ...

Currently, there are only two cell and gene therapies (CGTs) on the market across all gastroenterology (GI) indications. Anterogen's Cupistem, indicated for the treatment of anal fistula in adult ...

The United States market has shown robust performance, climbing 2.9% in the last 7 days and up 11% over the past year, with earnings projected to grow by 14% per annum in the coming years. In this ...